[1] HPS2- THRIVE Collaborative Group. Effects of extended
release niacin with laropiprant in high-risk patients [J]. N
Engl J Med, 2014,371(3):203-212.
[2] Amarenco P, Labreuche J, Touboul PJ. High-density lipopro?
tein-cholesterol and risk of stroke and carotid atherosclerosis: a
systematic review [J]. Atherosclerosis, 2008,196(2):489-
496.
[3] Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib
on the progression of coronary atherosclerosis [J]. N Engl J
Med, 2007,356(13):1304-1316.
[4] Mackey RH, Greenland P, Goff DC Jr, et al. High-density li?
poprotein cholesterol and particle concentrations, carotid ath?
erosclerosis, and coronary events: MESA (multi- ethnic study
of atherosclerosis) [J]. J Am Coll Cardiol, 2012,60(6):508-
516.
[5] AIM-HIGH Investigators. Niacin in patients with low HDL
cholesterol levels receiving intensive statin therapy [J]. N Engl
J Med, 2011,365(24):2255-2267.
[6] Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality
in Coronary Drug Project patients: long- term benefit
with niacin [J]. J Am Coll Cardiol, 1986,8(6):1245-1255.
[7] Grundy SM. An International Atherosclerosis Society Position
Paper: global recommendations for the management of dyslip?
idemia [J]. J Clin Lipidol, 2013,7(6):561-565.
[8] Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/
AHA Guideline on the Treatment of Blood Cholesterol to Re?
duce Atherosclerotic Cardiovascular Risk in Adults [J]. J Am
Coll Cardiol, 2014,63(25 Pt B):2889-2934
[9] Yang W, Xiao J, Yang Z, et al. Serum lipids and lipoproteins
in Chinese men and women [J]. Circulation, 2012,125(18):
2212-2221.
[10] 2014 年中国胆固醇教育计划血脂异常防治建议专家组.2014 年
中国胆固醇教育计划血脂异常防治专家建议[J].中华心血管病
杂志,2014,42(8):633-636.